Clinical Trials Logo

Microsatellite Instability clinical trials

View clinical trials related to Microsatellite Instability.

Filter by:

NCT ID: NCT03053466 Completed - Solid Tumor Clinical Trials

APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

Start date: March 27, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and recommended dose schedule of APL-501 in individuals with advanced or relapsed or recurrent solid tumors.

NCT ID: NCT03012581 Completed - Clinical trials for Carcinoma, Renal Cell

Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types

AcSé
Start date: June 16, 2017
Phase: Phase 2
Study type: Interventional

This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of nivolumab monotherapy in 6 cohorts of patients with specific rare cancers who have unresectable locally advanced or metastatic disease, which is resistant or refractory to standard therapy, or for which standard therapy does not exist, or is not considered appropriate, and for which no other experimental treatment options are available.

NCT ID: NCT02563002 Completed - Clinical trials for Colorectal Carcinoma

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Start date: November 30, 2015
Phase: Phase 3
Study type: Interventional

In this study, participants with stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal carcinoma (CRC) will be randomly assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for the treatment of advanced colorectal carcinoma. The primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS) or overall survival (OS) compared to current SOC chemotherapy.

NCT ID: NCT02178722 Completed - Lung Cancer Clinical Trials

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Start date: July 17, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.

NCT ID: NCT01876511 Completed - Clinical trials for MSI Positive Colorectal Cancer

Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

Start date: September 2013
Phase: Phase 2
Study type: Interventional

This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T cells) is effective (anti-tumor activity) and safe in three different patient populations. These include: 1. patients with MSI positive colon cancer, 2. patients with MSI negative colon cancer and 3. patients with other MSI positive cancers.

NCT ID: NCT00952874 Completed - HIV Infections Clinical Trials

Molecular Biology of Anal Cancer in HIV-Positive Patients

Start date: July 2009
Phase: N/A
Study type: Observational

The molecular mechanisms involved in squamous cell carcinoma of the anus (SCCA) are poorly elucidated. HIV-positive and renal transplant patients are at high risk for developing SCCA, indicating that immune suppression plays a facilitating role. The investigators previously demonstrated that chromosomal instability (CIN) was more prevalent in SCCA of HIV-negative than HIV-positive patients. Hence, the investigators postulate that microsatellite instability (MSI), another molecular pathway, might be a feature of SCCA progression in the HIV-positive population. Study Aims: 1. to determine the prevalence of MSI in paraffin-embedded tumor specimen of 15 patients from the Swiss HIV cohort who underwent surgical excision for SCCA; and 2. eventually, to test our hypothesis by assessing the MSI status of SCCA in 15 recently operated HIV-negative patients. Study Design: The study is designed in two steps: 1. Firstly, the investigators will retrieve tumor specimen from 15 HIV-positive patients, with a biopsy-confirmed diagnosis of SCCA, in three institutions. DNA from tumor and normal tissues will be extracted, and then amplified by PCR. Presence of MSI in tumors will be determined by assessing the microsatellite markers BAT25, BAT26, and CAT25. 2. Secondly, the results of molecular analysis will be compared with a population of HIV-negative patients, with the same tumors, using the same detection technique for MSI.

NCT ID: NCT00912743 Completed - Colorectal Cancer Clinical Trials

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Start date: May 2009
Phase: Phase 2
Study type: Interventional

This study is being carried out to see if the new drug, olaparib (AZD2281), can effectively and safely treat advanced large bowel cancer. The primary goal of this clinical trial is to determine whether olaparib will have a beneficial effect on the patient's cancer by causing a response and increasing the time it takes for the cancer to progress.

NCT ID: NCT00044967 Completed - Colorectal Cancer Clinical Trials

Genetic Study of Young Patients With Colorectal Cancer

Start date: May 2002
Phase: N/A
Study type: Observational

RATIONALE: Identifying gene mutations (microsatellite instability) may allow doctors to plan effective treatment for patients who develop colorectal cancer at an early age. PURPOSE: Genetic trial to determine the significance of gene mutations in helping predict the outcome of treatment in patients who develop stage I, stage II, or stage III colorectal cancer at an early age.